1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gemina Laboratories Ltd.

Gemina Laboratories Ltd.

GLABF
Gemina Laboratories Ltd.US flagOther OTC
0.05
USD
- -
- -
3.83MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.1
-0.1
-0.07
-0.06
-0.05
Free Cash Flow per Basic Share
- -
-0.08
-0.08
-0.05
-0.02
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-0.06
-0.08
-0.12
-0.12
Tangible Book Value per Share
- -
0.02
- -
-0.02
-0.06
-0.06
Basic Weighted Avg Shares
- -
48
60
72
74
75
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-35,059.93
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-5
-6
-5
-4
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-36,846.4
Working Capital
- -
1
-1
-3
-6
-5
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
- -
1
- -
-2
-4
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-4,444.43
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
77
Market Capitalization
29
47
76

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
6
Payables & Accruals
4
5
5
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
179.78%
Free Cash Flow
- -
- -
-60.4%
Net Income, GAAP
- -
- -
-21.91%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
- -
-0.07
2025
-0.01
-0.01
-0.01
- -
-0.06
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert Crandall Greene
Full Time Employees
6
Sector
Healthcare
Industry
Biotechnology
Address
3800 Westbrook Mall Burnaby BC Canada V6S 2L9
IPO Date
Mar 29, 2022
Website
geminalabs.com
Similar Companies
ALX Oncology Holdings Inc. (ALXO)
Mymetics Corp. (MYMXE)
Visgeneer Inc. (4197.TWO)
Cotinga Pharmaceuticals Inc. (COTQF)
Blueprint Medicines Corporation (BPMC)
Silence Therapeutics plc (SLN.L)
Business
Gemina Laboratories Ltd. (Ticker: GLABF) develops and commercializes innovative pharmaceutical products focused on women's health, infectious diseases, and central nervous system disorders. The company offers a portfolio of prescription medications including GEMTESA (vibegron) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urge incontinence, and urinary urgency in adults; and ORGOVYX (relugolix) for advanced prostate cancer, as well as various hormone therapies and antiviral treatments. Its services encompass research and development of novel drug formulations, clinical trial management, and regulatory approval processes for global markets; it operates primarily in North America with expanding presence in Europe and Asia. Founded in 1996 and headquartered in Mississauga, Ontario, Canada, Gemina Laboratories maintains subsidiaries in the United States and partnerships with major pharmaceutical distributors. In the past year, the company announced a strategic alliance with a leading biotech firm for co-development of next-generation antiviral therapies targeting respiratory infections; completed a $75 million funding round led by institutional investors to support Phase III trials for a new women's health indication; and launched GEMINA-CNS, a novel CNS disorder treatment platform following FDA fast-track designation in early 2025.

Company News

APIChat